Pancreatic cancer is an aggressive type of cancer with very little treatment options that are mostly disappointing especially in the advanced stages of disease, were the cancer has spread to other parts of the body, metastases.
Therefore, if these cancer patients and their families want to fight the disease and increase the chance, they really need to look into the forefront of science in this field.
Positive efficacy results were recently announced regarding a new antibody, a biological drug, Nadunolimab (CAN04) plus Gemzar/Abraxane in treating patients with pancreatic cancer in the first line setting.
About the CANFOUR study
The ongoing, open-label, phase 1/2a CANFOUR trial (NCT03267316) enrolled 36 patients with advanced pancreatic cancer, reporting the early efficacy data for the combination treatment in the first line setting.
- The median time the disease did not progress was 7.8 months
- The median survival was 12.6 months which is longer compared to the standard therapy
- Nine patients experienced response with a median duration of response of 6.8 months
About Pancreatic Cancer
This type of cancer is aggressive, since most of the patients are diagnosed in an advanced stage, where the disease is considered incurable, for the most part.
Pancreas cancer is hard to diagnose early since its symptoms do not usually appear in early stages.
The patient’s life expectancy is poor and currently stands on less than one year; this is with the support of the standard treatments.
Contact us so we can help you to actually get the most advanced treatments
Because we, do not give up on life!
Contact us 24/7 –
Call center +44.2082.426.039